How FDA Tracks Its Own Dietary Supplement CGMP Paperwork

Two Notices, One Underlying Rule

In February 2026 and again in June 2026, the Food and Drug Administration published Federal Register notices concerning the same subject: the paperwork associated with Current Good Manufacturing Practice (CGMP) requirements for dietary supplement manufacturing, packaging, labeling, and holding operations. Neither notice creates a new rule. Both are procedural steps required by a decades-old federal statute that governs how agencies collect information from regulated industries.

The February notice was a proposed collection comment request, published under the Paperwork Reduction Act (PRA) of 1995, which requires agencies to publish a Federal Register notice and allow 60 days for public comment whenever they seek to collect information from the public, including extensions of existing collections [SRC: FR-2026-03589]. The June notice announced that the resulting collection request had been submitted to the Office of Management and Budget (OMB) for review and clearance, the next formal step in the same statutory process [SRC: FR-2026-12238].

Understanding this sequence matters because it is easy to mistake a PRA notice for a substantive change to manufacturing law. It is not. The dietary supplement CGMP requirements themselves — codified separately in FDA regulation — already exist and already apply to manufacturers. What these two notices track is something narrower: how much time and cost the government estimates the recordkeeping and reporting portions of that existing rule impose on industry, and whether OMB will approve the continued collection of that information.

What the Paperwork Reduction Act Actually Requires

The PRA was designed to prevent federal agencies from imposing unnecessary or duplicative information-collection burdens on businesses and individuals. Under the statute, before an agency can require the public to fill out forms, keep specified records, or submit specified reports, it generally must estimate the burden, publish that estimate for public comment, and secure OMB approval. This applies even when the underlying substantive rule requiring the recordkeeping has been in effect for years.

For dietary supplement CGMP, this means the recordkeeping and documentation obligations that manufacturers already follow — batch production records, testing documentation, and similar requirements under the CGMP regulation — periodically come up for this paperwork review cycle. The February 2026 notice solicited public comment specifically on "the information collection provisions of FDA's regulations regarding current good manufacturing practice (CGMP) for dietary supplements," not on the manufacturing standards themselves [SRC: FR-2026-03589].

The June 2026 notice reflects the next procedural milestone: after considering any comments received, FDA submitted the collection request to OMB, which has its own review authority under the PRA before final clearance is granted [SRC: FR-2026-12238]. This is a routine administrative cycle that recurs for approved information collections; it is not evidence that FDA is proposing to rewrite CGMP substance, tighten enforcement, or add new manufacturing obligations.

What Counts as "Information Collection" Under CGMP

In the dietary supplement CGMP framework, the "information collection" burden generally refers to the recordkeeping and documentation activities manufacturers must already perform and retain — not to a new testing or labeling mandate. Neither notice in this packet specifies which particular records or estimated hour burdens are at issue; both are administrative notices about the review process itself rather than technical guidance documents detailing recordkeeping content. Readers seeking the specific line items — such as batch record retention periods or specification documentation — should consult the CGMP regulation text directly, since these PRA notices are procedural markers, not substantive rule text.

Mandatory Requirement vs. Agency Process: A Clear Line

This distinction is not a technicality. Trade press and marketing materials sometimes conflate a PRA notice with "FDA cracking down" or "FDA updating supplement rules." Both characterizations overstate what a paperwork clearance notice does. The notices confirm that an existing, previously approved information collection tied to CGMP is being renewed through the standard federal review cycle; they do not signal enforcement priorities, new inspection criteria, or amended manufacturing standards.

Why This Process Exists at All

The PRA cycle for CGMP recordkeeping is not unique to dietary supplements. Every FDA-regulated industry with recordkeeping obligations — drugs, medical devices, food — has analogous PRA-driven collection requests that recur on a schedule, generally every three years, unless intervening circumstances trigger earlier action. The dietary supplement CGMP information collection appearing again in a 2026 comment cycle is consistent with that routine schedule rather than indicative of a special review triggered by a specific incident or policy shift. Nothing in either notice in this packet identifies a triggering event, complaint, or enforcement action prompting the review.

For manufacturers, the practical relevance of these notices is limited to the comment and OMB-clearance process itself: the opportunity to weigh in on burden estimates, not an opportunity to weigh in on the underlying CGMP standard. The public comment period referenced in the February notice was procedural — commenters could address, for instance, whether FDA's estimate of hours needed to comply with recordkeeping is realistic — not a forum for renegotiating what CGMP requires substantively [SRC: FR-2026-03589].

Limits of the Evidence

These two Federal Register notices are narrow administrative documents. They do not describe the substantive content of the CGMP regulation, do not quantify the actual hour or cost burden FDA estimated, do not indicate whether OMB ultimately approved the collection, and do not signal any change in FDA's inspection or enforcement posture toward dietary supplement manufacturers. Readers should not interpret either notice as a summary of CGMP requirements, a signal of new obligations, or an indication that FDA is revisiting the underlying manufacturing standard. Both documents are procedural notices under the Paperwork Reduction Act, and their scope should be read no more broadly than that.

Because neither source in this packet provides the actual regulatory text of the CGMP rule, this article cannot and does not summarize what dietary supplement CGMP substantively requires manufacturers to do on the production floor. That information lives in a separate part of the Code of Federal Regulations and would require its own sourced review.

What This Does Not Mean

• It does not mean FDA has proposed new CGMP manufacturing standards for dietary supplements.
• It does not mean the comment period changed any binding requirement — comments addressed burden estimates, not substantive rule content [SRC: FR-2026-03589].
• It does not mean OMB clearance, once granted, alters what manufacturers are already required to do under existing CGMP regulation.
• It does not mean this cycle was triggered by a specific enforcement action, recall, or safety concern; no such trigger appears in either notice.

Selected Sources

• FR-2026-12238: OMB Review Submission Notice, June 18, 2026
• FR-2026-03589: Proposed Collection Comment Request, February 24, 2026

Editorial note: This article summarizes publicly available Federal Register procedural notices for educational purposes. It does not constitute legal advice or a comprehensive summary of dietary supplement CGMP regulatory requirements.

This article is for educational purposes and has not been evaluated by the Food and Drug Administration. It is not intended to diagnose, treat, cure, or prevent any disease.